RAD51 Linked With PARP Inhibitor Resistance in BRCA-Mutated Breast Cancer

Leggi l'articolo originale


A biomarker known as RAD51 was found to be correlated with resistance to PARP inhibitor treatment in a study of breast cancer that harbors BRCA mutations.

Lascia un commento